← Evidence map

ArticleImmunotherapy advances2025

Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system.

Kristýna Šmilauerová et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. | OpenQuestion